KOAH Bülteni 2012 Sayı 1

degerlendirme
-
Respir J 2008;( 31) 927–33.
15. Suissa S, Barnes PJ. Inhaled corticosteroids in
COPD: the case against. Eur Respir J 2009; 34:13–
6.
16. Rabe KF, Hurd S, Anzueto A et al. Global strategy
for the diagnosis, management, and prevention of
COPD – 2006 Update. Am J Respir Crit Care Med
2007;176:532–55.
17. Drummond MB, Dasenbrook EC, Pitz MW et al.
Inhaled corticosteroids in patients with stable
chronic obstructive pulmonary disease: a systematic
review and meta-analysis. JAMA 2008;300:
2407–16.
18. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids
and the risks of diabetes onset and progression.
Am J Med 2010;123:1001-6.
19. Singh S, Loke YK. An overview of the benefits and
drawbacks of inhaled corticosteroids in chronic
obstructive pulmonary disease. Int. J. Chron.
Obstruct. Pulmon Dis.2010; 5:189–195.
20. Barnes P. Triple inhalers for obstructive airways
disease: will they be useful? Expert Rev Respir
Med 2011;5:297–300.
21. Donohue JF, van Noord JA, Bateman ED, et al.
A 6-month, placebo-controlled study comparing
lung function and health status changes in COPD
patients treated with tiotropium or salmeterol.
Chest 2002;122:47-5.
22. Niewoehner DE, Rice K, Cote C, et al. Prevention
of exacerbations of chronic obstructive pulmonary
disease with tiotropium, a once-daily inhaled anticholinergic
bronchodilator: a randomized trial.
Ann Intern Med 2005;143:317-26.
23. Mahler DA, Donohue JF, Barbee RA,et al. Efficacy
of salmeterol xinafoate in the treatment of COPD.
Chest 1999;115:957-65.
24. Mahler DA, Wire P, Horstman D, et al. Effectiveness
of fluticasone propionate and salmeterol
combination delivered via the Diskus device in the
treatment of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2002;166:1084-91.
25. Hanania NA, Darken P, Horstman D,et al. The efficacy
and safety of fluticasone propionate (250
microg)/salmeterol (50microg) combined in the
Diskus inhaler for the treatment of COPD. Chest
2003;124:834-43.
26. Nannini LJ, Cates CJ, Lasserson TJ, Poole P:
Combined corticosteroid and long-acting beta-agonist
in one inhaler versus placebo for chronic
obstructive pulmonary disease. Cochrane Database
Syst Rev 2007;4:CD003794.
27. Nannini LJ, Cates CJ, Lasserson TJ, Poole P:
Combined corticosteroid and long-acting beta-agonist
in one inhaler versus long-acting beta-agonists
for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev 2007;4:CD006829.
28. Nannini LJ, Cates CJ, Lasserson TJ, Poole P:
Combined corticosteroid and long-acting beta-agonist
in one inhaler versus inhaled steroids for
chronic obstructive pulmonary disease. Cochrane
Database Syst Rev 2007;4:CD006826.
29. Soriano JB, Kiri VA, Pride NB, Vestbo J: Inhaled
corticosteroids with/without long-acting beta-agonists
reduce the risk of rehospitalization and death
in COPD patients. Am J Respir Med 2003;2:67-74.
30. Aaron SD, Vandemheen KL, Fergusson D, et al:
Canadian Thoracic Society/Canadian Respiratory
Clinical Research Consortium. Tiotropium in
combination with placebo, salmeterol, or fluticasone-salmeterol
for treatment of chronic obstructive
pulmonary disease: a randomized trial. Ann
Intern Med 2007;146:545-555.
31. Short PM, Williamson PA, Elder DH, et al. The
impact of tiotropium on mortality and exacerbations
when added to inhaled corticosteroids and
long-acting β-agonist therapy in COPD. Chest.
2012;141:81-6.
32. Chazan RC. New drugs in chronic obstructive
pulmonary disease]. Pneumonol Alergol Pol.
2011;79:232-8.
33. Perng DW, Wu CC, Su KC,et al. Additive benefits of
tiotropium in COPD patients treated with long-acting
beta agonists and corticosteroids. Respirology
2006;11:598-602.
34. Singh D, Brooks J, Hagan G,et al. Superiority of
triple therapy with salmeterol/fluticasone propionate
and tiotropium bromideversus individual
components in moderate to severe COPD. Thorax
2008;63:592-8.
35. Welte R, Miravitlles M, Hernandez P, et al. Efficacy
and tolerability of budesonide/formoterol added
to tiotropium in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med
2009;180:741-50.
36. Welte T: Optimising treatment for COPD—new
strategies for combination therapy. Int J Clin Pract
2009;63:1136-49.
37. Hanania NA, Crater GD, Morris AN, et al. Benefits
of adding fluticasone propionate/salmeterol to
tiotropium in moderate to severe COPD. Respiratory
Medicine 2012;106:91-101.
38. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes
for COPD pharmacological trials: from lung
function to biomarkers. Eur Respir J 2008;31:416-
68.)
39. Karner C, Cates CJ. Combination inhaled steroid
and long-acting b(2)-agonist in addition to tiotropium
versus tiotropium or combination alone for
chronic obstructive pulmonary disease. Cochrane
Database Syst Rev. 2011;3:CD008532.
40. Jung KS, Park HY, Park SY, et al. Comparison of
tiotropium plus fluticasone propionate/salmeterol
with tiotropium in COPD: a randomized controlled
study. Respir Med. 2012;106:382-9.
41. Russell R, Anzueto A, Weisman I. Optimizing
management of chronic obstructive pulmonary
disease in the upcoming decade. Inter J COPD
2011;6:47-61.
12